[go: up one dir, main page]

BRPI0409911A - método para liberar uma molécula em uma célula, e, complexo carreador - Google Patents

método para liberar uma molécula em uma célula, e, complexo carreador

Info

Publication number
BRPI0409911A
BRPI0409911A BRPI0409911-7A BRPI0409911A BRPI0409911A BR PI0409911 A BRPI0409911 A BR PI0409911A BR PI0409911 A BRPI0409911 A BR PI0409911A BR PI0409911 A BRPI0409911 A BR PI0409911A
Authority
BR
Brazil
Prior art keywords
cell
molecule
release
carrier
carrier complex
Prior art date
Application number
BRPI0409911-7A
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Alex V Birk
D Robertson Hugh
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of BRPI0409911A publication Critical patent/BRPI0409911A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)

Abstract

"MéTODO PARA LIBERAR UMA MOLéCULA EM UMA CéLULA, E, COMPLEXO CARREADOR". A invenção refere-se aos complexos carreadores e aos métodos para liberar moléculas em células. Os complexos carreadores compreendem uma molécula e um peptídeo catiónico aromático de acordo com a invenção. Em uma modalidade, o método para liberar uma molécula em uma célula compreende contatar a célula com um complexo carreador. Em outra modalidade, o método para liberar uma molécula em uma célula compreende contatar a célula com um peptídeo catiónico aromático.
BRPI0409911-7A 2003-05-01 2004-05-03 método para liberar uma molécula em uma célula, e, complexo carreador BRPI0409911A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46751603P 2003-05-01 2003-05-01
PCT/US2004/013772 WO2005001023A2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells

Publications (1)

Publication Number Publication Date
BRPI0409911A true BRPI0409911A (pt) 2006-04-25

Family

ID=33551404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409911-7A BRPI0409911A (pt) 2003-05-01 2004-05-03 método para liberar uma molécula em uma célula, e, complexo carreador

Country Status (17)

Country Link
US (6) US7704954B2 (pt)
EP (7) EP2604287B1 (pt)
JP (6) JP4879020B2 (pt)
KR (1) KR101161823B1 (pt)
CN (2) CN101214380A (pt)
AU (1) AU2004252419B2 (pt)
BR (1) BRPI0409911A (pt)
CA (1) CA2524258C (pt)
DK (4) DK2604285T3 (pt)
ES (3) ES2520816T3 (pt)
MX (1) MXPA05011773A (pt)
NZ (1) NZ543410A (pt)
PL (2) PL2604286T3 (pt)
PT (2) PT2604285E (pt)
SI (1) SI2604285T1 (pt)
WO (1) WO2005001023A2 (pt)
ZA (1) ZA200509229B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
DK2604285T3 (en) 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
CN1938042B (zh) 2004-01-23 2010-06-02 科内尔研究基金会 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
KR20140042940A (ko) 2005-09-16 2014-04-07 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
EP1942925B1 (en) * 2005-11-04 2010-08-25 Forhumantech Co., Ltd. Methods for fusion polypeptide delivery into a cell
CN101490080A (zh) * 2006-07-24 2009-07-22 为人技术株式会社 用于缓解和治疗缺血性病症的药物组合物及其输送方法
US20080132450A1 (en) * 2006-08-29 2008-06-05 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
SI2252312T1 (sl) 2008-02-07 2014-08-29 Cornell University, Postopki za preprečevanje ali zdravljenje insulinske rezistence
WO2009108695A2 (en) 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
CN102482336B (zh) * 2008-09-22 2015-05-06 爱勒让治疗公司 拟肽大环化合物
WO2010060112A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
HUE029550T2 (en) * 2009-08-12 2017-03-28 Univ Cornell Methods of preventing or treating metabolic syndrome
PT2470191E (pt) 2009-08-24 2014-06-12 Stealth Peptides Int Inc Métodos e composições para prevenção ou tratamento de doenças oftálmicas
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell CATIONIC AROMATIC PEPTIDES AND USES THEREOF
JP2014518213A (ja) * 2011-06-14 2014-07-28 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチド及びその使用
JP6025311B2 (ja) 2011-08-01 2016-11-16 キヤノン株式会社 眼科診断支援装置および方法
CN103987397A (zh) 2011-09-29 2014-08-13 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
AU2012347931A1 (en) 2011-12-09 2014-07-03 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1210962A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2015134096A1 (en) * 2014-03-03 2015-09-11 Stealth Peptides International, Inc. Pharmaceutically relevant aromatic-cationic peptides
EP3148565A4 (en) * 2014-05-28 2018-06-06 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3149035A4 (en) * 2014-05-28 2018-05-16 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
US10125164B2 (en) 2014-06-25 2018-11-13 Flamma S.P.A. Process for preparing D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016209261A1 (en) * 2015-06-26 2016-12-29 Stealth Biotherapeutics Corp Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof, and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
WO2017070578A1 (en) 2015-10-21 2017-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN110087685A (zh) 2016-11-16 2019-08-02 卢卡科学株式会社 用于治疗和/或预防心力衰竭的心肌干细胞的制造方法
US20190380958A1 (en) * 2016-12-28 2019-12-19 Chugai Seiyaku Kabushiki Kaisha Self-emulsifying drug formulation for improving membrane permeability of compound
CN107230021B (zh) * 2017-06-08 2020-05-26 桂林理工大学 筛选供水管网泄漏区域的方法
AU2019293857A1 (en) * 2018-06-29 2020-12-10 Glykos Finland Oy Conjugates
EP4081192A2 (en) 2019-12-27 2022-11-02 LUCA Science Inc. Isolated mitochondria with smaller size and lipid membrane-based vesicles encapsulating isolated mitochondria
WO2021216499A1 (en) * 2020-04-23 2021-10-28 North Carolina State University Cell-penetrating peptide-microrna conjugates for intracellular cell delivery
JP2023541403A (ja) 2020-09-09 2023-10-02 ソーシャル・プロフィット・ネットワーク ビオチンをミトコンドリアに送達するための方法及び組成物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500053A (pt) * 1978-01-16 1980-01-31
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP2071036A3 (en) * 1999-10-04 2009-09-09 The University of Medicine and Dentistry of New Jersey Methods for identifying RNA-binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
CA2416475C (en) * 2000-07-18 2011-10-11 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
CA2437983C (en) * 2001-02-16 2011-10-25 Cellgate, Inc. Transporters comprising spaced arginine moieties
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
DK2604285T3 (en) * 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CN1938042B (zh) * 2004-01-23 2010-06-02 科内尔研究基金会 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
KR20140042940A (ko) * 2005-09-16 2014-04-07 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
SI2252312T1 (sl) * 2008-02-07 2014-08-29 Cornell University, Postopki za preprečevanje ali zdravljenje insulinske rezistence
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
US10955715B2 (en) 2018-06-29 2021-03-23 Reald Spark, Llc Optical stack for privacy display

Also Published As

Publication number Publication date
PT2604286E (pt) 2014-11-28
JP2018158951A (ja) 2018-10-11
JP5650040B2 (ja) 2015-01-07
JP2014221846A (ja) 2014-11-27
EP3167935A1 (en) 2017-05-17
NZ543410A (en) 2008-07-31
EP2604286B1 (en) 2014-08-27
US20100204448A1 (en) 2010-08-12
US20170035899A1 (en) 2017-02-09
CN100506841C (zh) 2009-07-01
ES2694574T3 (es) 2018-12-21
US11845807B2 (en) 2023-12-19
ES2520815T3 (es) 2014-11-11
HK1186407A1 (en) 2014-03-14
EP2604287B1 (en) 2016-12-07
EP3381515B1 (en) 2020-07-08
PT2604285E (pt) 2014-11-12
EP1625149B1 (en) 2016-02-17
AU2004252419B2 (en) 2010-02-18
HK1186482A1 (en) 2014-03-14
US9315586B2 (en) 2016-04-19
EP3381515A1 (en) 2018-10-03
US20200299415A1 (en) 2020-09-24
EP2604285A1 (en) 2013-06-19
SI2604285T1 (sl) 2014-12-31
KR101161823B1 (ko) 2012-07-03
US7704954B2 (en) 2010-04-27
CN101214380A (zh) 2008-07-09
US20220372172A1 (en) 2022-11-24
US8148322B2 (en) 2012-04-03
EP1625149A4 (en) 2010-10-06
HK1186406A1 (en) 2014-03-14
DK2604285T3 (en) 2014-12-01
JP2011168603A (ja) 2011-09-01
DK1625149T3 (en) 2016-05-30
EP1625149A2 (en) 2006-02-15
DK2604286T3 (en) 2014-12-08
EP2604285B1 (en) 2014-08-27
HK1253888A1 (en) 2019-07-05
JP4879020B2 (ja) 2012-02-15
JP5995930B2 (ja) 2016-09-21
MXPA05011773A (es) 2006-02-17
EP2604621B1 (en) 2015-10-21
CA2524258A1 (en) 2005-01-06
US10584182B2 (en) 2020-03-10
JP6395749B2 (ja) 2018-09-26
ZA200509229B (en) 2007-03-28
EP2604286A1 (en) 2013-06-19
US20130085259A1 (en) 2013-04-04
JP6698756B2 (ja) 2020-05-27
HK1089450A1 (zh) 2006-12-01
HK1231424A1 (en) 2017-12-22
JP2016130246A (ja) 2016-07-21
EP2604287A3 (en) 2014-04-16
EP3167935B1 (en) 2018-07-18
US20050158373A1 (en) 2005-07-21
ES2520816T3 (es) 2014-11-11
JP2020105184A (ja) 2020-07-09
US11180574B2 (en) 2021-11-23
CN1780851A (zh) 2006-05-31
WO2005001023A3 (en) 2005-04-28
AU2004252419A1 (en) 2005-01-06
EP2604621A1 (en) 2013-06-19
PL2604286T3 (pl) 2015-03-31
DK2604621T3 (en) 2016-02-01
CA2524258C (en) 2012-08-07
PL2604285T3 (pl) 2015-02-27
EP2604287A2 (en) 2013-06-19
KR20060008950A (ko) 2006-01-27
WO2005001023A2 (en) 2005-01-06
JP2007503461A (ja) 2007-02-22

Similar Documents

Publication Publication Date Title
BRPI0409911A (pt) método para liberar uma molécula em uma célula, e, complexo carreador
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
BR0016520A (pt) Processo para a redução eletroquìmica de corantes reduzìveis
DE602006015292D1 (de) Zuführung von molekülen an eine lipiddoppelschicht
BRPI0513933A (pt) sistema e método para intercalação de diversidade
NO20065084L (no) Interferon-alfa polypeptider og konjugater
BR0315273B1 (pt) sistema compressor eletroquÍmico, placa bipolar, sistema de cÉlula de combustÍvel, e, processo para produzir uma placa bipolar.
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
ATE494012T1 (de) Stabilisierte polymer-thiol-reagenzien
IL189595A0 (en) Hydrogel functionalized with a polymerizable moiety and their uses as biosensors or bioreactors
DE60239729D1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
WO2008094945A3 (en) Compounds and methods for modulating protein expression
ATE520165T1 (de) Gasdiffusionseinheit für eine brennstoffzelle
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
BR0201414B1 (pt) sapata para uso em um compressor do tipo de prato giratório, bem como compressor do tipo de prato giratório.
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
WO2004108749A3 (en) Binding peptides: methods for their generation and use
BR0213191B1 (pt) processo para reciclagem de gás de processo em um processo eletroquìmico.
BRPI0517904A (pt) uso de polìmeros, e, processo para imprimir por meio da técnica offset
BR8201194Y1 (pt) disposição construtiva introduzida em suporte para botijão de gás com sistema para supervisão de consumo à distáncia.
ATE397691T1 (de) Papierherstellung mit modifizierten kieselsolen als mikropartikel
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
DE50113417D1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
WO2005089509A3 (en) High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
BRPI0408023A (pt) métodos para previnir gliconoilação de proteìnas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]